A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
King, Marie A.Pearson, Todd
Shultz, Leonard D.
Leif, Jean H.
Bottino, Rita
Trucco, Massimo
Atkinson, Mark A.
Wasserfall, Clive
Herold, Kevan C.
Woodland, Robert T.
Schmidt, Madelyn R.
Woda, Bruce A.
Thompson, Michael J.
Rossini, Aldo A.
Greiner, Dale L.
Student Authors
Marie KingUMass Chan Affiliations
Department of PhysiologyDepartment of Molecular Genetics and Microbiology
Department of Pathology
Department of Medicine, Division of Diabetes
Document Type
Journal ArticlePublication Date
2007-12-22Keywords
Animals; Diabetes Mellitus; Disease Models, Animal; Graft Rejection; Humans; Interleukin Receptor Common gamma Subunit; Islets of Langerhans; Islets of Langerhans Transplantation; Leukocytes, Mononuclear; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Mutation; PhenotypeAllergy and Immunology
Endocrinology, Diabetes, and Metabolism
Immunology and Infectious Disease
Life Sciences
Medicine and Health Sciences
Metadata
Show full item recordAbstract
Immunodeficient NOD-scid mice bearing a targeted mutation in the IL2 receptor common gamma chain (Il2rgamma(null)) readily engraft with human stem cells. Here we analyzed human peripheral blood mononuclear cells (PBMC) for their ability to engraft NOD-scid Il2rgamma(null) mice and established engraftment kinetics, optimal cell dose, and the influence of injection route. Even at low PBMC input, NOD-scid Il2rgamma(null) mice reproducibly support high human PBMC engraftment that plateaus within 3-4 weeks. In contrast to previous stocks of immunodeficient mice, we observed low intra- and inter-donor variability of engraftment. NOD-scid Il2rgamma(null) mice rendered hyperglycemic by streptozotocin treatment return to normoglycemia following transplantation with human islets. Interestingly, these human islet grafts are rejected following injection of HLA-mismatched human PBMC as evidenced by return to hyperglycemia and loss of human C-peptide. These data suggest that humanized NOD-scid Il2rgamma(null) mice may represent an important surrogate for investigating in vivo mechanisms of human islet allograft rejection.Source
Clin Immunol. 2008 Mar;126(3):303-14. Epub 2007 Dec 21. Link to article on publisher's siteDOI
10.1016/j.clim.2007.11.001Permanent Link to this Item
http://hdl.handle.net/20.500.14038/33687PubMed ID
18096436Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.clim.2007.11.001